发明名称 |
CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE |
摘要 |
There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial. |
申请公布号 |
US2014235606(A1) |
申请公布日期 |
2014.08.21 |
申请号 |
US201414262863 |
申请日期 |
2014.04.28 |
申请人 |
AstraZeneca AB |
发明人 |
Gullberg Britt Anne Ingela;Larsson Thomas Peter;Stonehouse Jeffrey Paul |
分类号 |
C07D403/12;A61K45/06;A61K31/506 |
主分类号 |
C07D403/12 |
代理机构 |
|
代理人 |
|
主权项 |
1. A crystalline form of N-[2-[[(2,3-di:fluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide (also referred to as “Compound I”), characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 A, comprising at least one crystalline peak with a 2-Theta value (in degrees) of 21.0, 28.8 and/or 29.1. |
地址 |
Sodertalje SE |